- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
8th grade Avg
|
- 10-K Annual report
- 2.4 Settlement Agreement and Mutual Release
- 2.5 Amendment to Securities Purchase Agreement
- 2.6 Amendment to License Agreement
- 10.18 Severance Agreement and Release for Jeffrey Landau
- 10.24 License Agreement Dated Oct. 15, 2004 BTWN Biomarin and DSP
- 10.25 License Agreement Dated July 30, 2004 BTWN Biomarin and DSP
- 10.26 Supply Agreement Dated July 30, 2004 BTWN Biomarin and DSP
- 10.37 Second Agreement to Loan and Security Agreement
- 10.38 Convertible Promissory Note Dated Jan 12, 2005
- 10.39 Cro Services Agreement Dated Sep. 15, 2004
- 21.1 List of Subsidiaries
- 23.1 Consent of KPMG LLP
- 23.2 Consent of Pricewaterhousecoopers LLP
- 31.1 Certification of CEO and CFO (Section 906)
- 31.2 CFO Certification
- 32.1 Certification of CEO and CFO (Section 906)
- 99.1 Biomarin/genzyme LLC Financial Statements
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
The Board of Directors
BioMarin Pharmaceutical Inc.:
We consent to the incorporation by reference in (i) the Registration Statements on Form S-8 (File Nos. 333-84787 and 333-85368) and (ii) the Registration Statements on Form S-3 (File Nos. 333-102066 and 333-108972) of BioMarin Pharmaceutical Inc. of our reports dated March 16, 2005, with respect to the consolidated balance sheets of BioMarin Pharmaceutical Inc. as of December 31, 2004 and 2003, and the related consolidated statements of operations, changes in stockholders’ equity (deficit) and cash flows for each of the years in the three-year period ended December 31, 2004, and the related financial statement schedule, management’s assessment of the effectiveness of internal control over financial reporting as of December 31, 2004, and the effectiveness of internal control over financial reporting as of December 31, 2004, which reports appear in the December 31, 2004, annual report on Form 10-K of BioMarin Pharmaceutical Inc.
/s/ KPMG LLP
San Francisco, California
March 16, 2005